Draft:OPC-64005
 | Review waiting, please be patient.
This may take 6 weeks or more, since drafts are reviewed in no specific order. There are 1,215 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
| Clinical data | |
|---|---|
| Other names | OPC64005 |
| Routes of administration | Oral[1] |
| Drug class | Serotonin–norepinephrine–dopamine reuptake inhibitor (triple reuptake inhibitor)[1] |
OPC-64005 is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), or "triple reuptake inhibitor" (TRI), which is under development for the treatment of major depressive disorder.[1][2][3] It was also under development for the treatment of attention deficit hyperactivity disorder (ADHD), but development for this indication was discontinued.[1][4] It is taken by mouth.[1]
As of December 2022, OPC-64005 is in phase 2 clinical trials for major depressive disorder.[1][2] It reached phase 2 clinical trials for ADHD prior to the discontinuation of its development for this use.[1] It completed a phase 2 clinical trial for ADHD comparing it with placebo and atomoxetine, but the results of this trial were not disclosed.[5] The drug is under development by Otsuka Pharmaceutical.[1][2] It is a small molecule, but its chemical structure does not appear to have been disclosed.[1][2]
References
[edit]- ^ a b c d e f g h i "OPC 64005". AdisInsight. 7 December 2022. Retrieved 22 October 2024.
- ^ a b c d "Delving into the Latest Updates on OPC-64005 with Synapse". Synapse. 17 October 2024. Retrieved 22 October 2024.
- ^ Rodríguez-Lavado J, Alarcón-Espósito J, Mallea M, Lorente A (August 2022). "A New Paradigm Shift in Antidepressant Therapy: From Dual-action to Multitarget-directed Ligands". Curr Med Chem. 29 (29): 4896–4922. doi:10.2174/0929867329666220317121551. PMID 35301942.
- ^ Nageye F, Cortese S (July 2019). "Beyond stimulants: a systematic review of randomised controlled trials assessing novel compounds for ADHD". Expert Rev Neurother. 19 (7): 707–717. doi:10.1080/14737175.2019.1628640. PMID 31167583.
- ^ Williams OC, Prasad S, McCrary A, Jordan E, Sachdeva V, Deva S, Kumar H, Mehta J, Neupane P, Gupta A (May 2023). "Adult attention deficit hyperactivity disorder: a comprehensive review". Ann Med Surg (Lond). 85 (5): 1802–1810. doi:10.1097/MS9.0000000000000631. PMC 10205222. PMID 37228994.
 | This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it. |